Interstitial Lung Disease (ILD) & Idiopathic Pulmonary Fibrosis (IPF)

Interstitial Lung Disease is a large group of lung disorders associated with inflammation and scarring of lung tissue. It is comprised of over 100 disorders that include Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Sarcoidosis, Connective Tissue or Auto Immune related ILD and many others. The inflammation/scarring of this group of diseases decrease the lungs ability to receive oxygen. They are often symptomatic for shortness of breath and a dry cough. The diseases can be difficult to diagnose and vary from patient to patient. That is why the Interstitial Lung Disease Clinic at MUSC has the most current diagnostic and therapeutic modalities available. We take a multidisciplinary approach to the personalized care of our patients. 

Idiopathic Pulmonary Fibrosis is a type of chronic interstitial lung disease of unknown etiology characterized by the scarring of the lungs resulting in decreased lung function. Typical characteristics of the disease include progressive dyspnea, unproductive cough, and pulmonary insufficiency. It is more common in men than women.

Pulmonary Fibrosis Support Group Meeting:

When: October 4, 2021 | 1:30 to 3:30 pm

Featured Speakers: Dr. Timothy Whelan will be speaking on "Covid-19 and the Covid-19 Vaccine" and Dr. Kathleen Oare Lindell will present "Addressing Your Future for Both Patients and Caregivers."

Where: Attend in person or virtually via Microsoft Teams

In Person: Ashley River Tower, 1st Floor Auditorium, 25 Courtenay Drive, Charleston, SC

Join Virtually 
*If you are using an iphone or Android phone, you will be prompted to download the Microsoft Teams app to access the meeting.

For more information and to RSVP, please contact Deborah Spehar at or 843-792-9714.

Clinical Trials

 At MUSC our physicians have expertise in the diagnosis and differentiation of IPF. There is currently no known cure for the disease. MUSC is actively involved in research and clinical trials to identify treatments and therapies that may slow the progression IPF. Learn how to enroll current clinical trials

Our Care Team

More Care Team Members

Katie Shoptaw | ILD Nurs Coordinator